AzTTP

For general laboratory use.

Envio: shipped on gel packs

Condições de armazenamento: store at -20 °C
Short term exposure (up to 1 week cumulative) to ambient temperature possible.

Validade: 12 months after date of delivery

Fórmula molecular: C10H16N5O13P3 (free acid)

Peso molecular: 507.18 g/mol (free acid)

CAS#: 906479-25-2

Pureza: ≥ 95 % (HPLC)

Forma: solution in water

Concentração: 100 mM - 110 mM

pH: 7.5 ±0.5

Propriedades espectroscópicas: λmax 267 nm, ε 10.9 L mmol-1 cm-1 (Tris-HCl pH 7.5)

Formulários:
Suppression of HIV-type 1 replication^[1]
Removal of iron from transferrin^[2]
Inhibition of telomerase activity^[3]
Inhibition of thymidine phosphorylation^[4]

Specific Ligands:

High binding affinity to HIV-1 mutants[5]

Referências selecionadas:
[1] Sayed et al. (2009) AZT 5'-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells. J. Neurobiology 15 (4):343.

[2] D´Andrea et al. (2008) AZT: an old drug with new perspectives. Curr. Clin. Pharmacol. 3 (1):20.

[3] Liu et al. (2007) 3'-Azido-2´,3'-dideoxynucleoside 5'-triphosphates inhibit telomerase activity in vitro, and the corresponding nucleosides cause telomere shortening in human HL60 cells. Nucleic Acid Res. 35 (21):7140.

[4] Lynx et al. (2006) 3'-Azido-3'-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: A possible mechanism of AZT hepatotoxicity. Biochem. Pharmacol. 71 (9):1342.

[5] Jamburuthugoda et al. (2005) Kinetic evidence for interaction of HIV type 1 reverse transcriptase with the 3'-OH of the incoming dTTP substrate. Biochemistry 44 (31):10635.

Coulier et al. (2008) Simultaneous determination of endogenous deoxynucleotides and phosphorylated nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cells using ion-pair liquid chromatography coupled to mass spectrometry. Proteomics Clin. Appl. 2:1557.

Cruchaga et al. (2005) Inhibition of Phosphorolysis Catalyzed by HIV-1 Reverse Transcriptase Is Responsible for the Synergy Found in Combinations of 3'-Azido-3'-deoxythymidine with Nonnucleoside Inhibitors Biochemistry 44 (9):3535.

Akeb et al. (2001) The production and evaluation of antibodies for enzyme immunoassay of AZTTP. Nucleosides Nucleotides Nucleic Acids. 20:243.

Fletcher et al. (2000) Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIVinfected persons. AIDS 14:2137.

Faraj et al. (2000) Effects of beta-L-3'-azido-3'-deoxythymidine 5'-triphosphate on host and viral DNA polymerases. Antiviral Res. 47:97.

Font et al. (1999) Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry. Antimicrob. Agents Chemother. 43:2964.

Elimadi et al. (1997) Differential effects of zidovudine and zidovudine triphosphate on mitochondrial permeability transition and oxidative phosphorylation. Br. J. Pharmacol. 121:1295.

Jaju et al. (1995) Human immunodeficiency virus type 1 reverse transcriptase. 3'-Azidodeoxythymidine 5'-triphosphate inhibition indicates two-step binding for template-primer. J. Biol. Chem. 270:9740.

Tornevik et al. (1995) Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem. Pharmacol. 49:829.